ImmunityBio (NASDAQ:IBRX), a commercial-stage biotechnology firm, reported on April 9, 2026, that preliminary net product revenue for the first quarter reached approximately $44.2 million.
The results represent a 168% increase compared to the first quarter of 2025 and mark the fourth consecutive quarter of growth since the commercial launch of its flagship immunotherapy, ANKTIVA.
The first-quarter performance builds on a transformative 2025 fiscal year, in which the company generated $113 million in net product revenue—a 700% increase over 2024 levels.
On a sequential basis, the $44.2 million figure represents a 15% increase over the $38.3 million earned during the final quarter of 2025, signaling sustained demand for the treatment in its initial indications.
Beyond financial metrics, the company reached significant regulatory and clinical milestones during the period.
ANKTIVA is now approved or authorized in five regulatory jurisdictions, covering approximately 34 countries.
In the clinical pipeline, ImmunityBio confirmed that its pivotal QUILT-2.005 trial for BCG-naïve carcinoma in situ (CIS) is now fully enrolled.
The Independent Data Monitoring Committee (IDMC) has confirmed that no additional enrollment is required, keeping the company on track for a supplemental Biologics License Application (sBLA) submission later in 2026.
Financially, ImmunityBio ended the quarter with an estimated $380.9 million in cash, cash equivalents, and marketable securities.
This liquidity position is expected to provide the necessary runway to support the continued commercial rollout of ANKTIVA and the advancement of its broader immunotherapy pipeline targeting various solid tumors.